How I Can Help
Explore the range of strategic HEOR, HTA and market access advisory services I offer. Every engagement is tailored to the needs of your asset, market and stage of development. If you do not see exactly what you are looking for, please get in touch to discuss a bespoke solution.
Global Market Access Strategy
I work with pharmaceutical and biotech companies to develop evidence-led market access strategies tailored to diverse international healthcare systems, health technology assessment (HTA) & reimbursement frameworks.
Drawing on extensive experience across Europe, the UK and established international markets, I help clients navigate complex access pathways, align global and local evidence requirements, and strengthen launch readiness.
Whether supporting mature brands entering new markets or launch-phase assets, I focus on creating clear, credible strategies that maximise HTA success, reimbursement potential and long-term patient access.
Typical areas include:
• launch access strategy
• reimbursement pathway planning
• global-to-local evidence alignment
• payer landscape analysis
• pricing and value strategy
HTA Strategy
I provide senior strategic advisory across national and international HTA pathways.
My focus is on ensuring evidence is positioned effectively to withstand HTA scrutiny, optimise comparator and endpoint strategy, and strengthen HTA and reimbursement outcomes.
I work closely with cross-functional teams to shape payer-relevant value narratives and address evidence risks early.
Typical areas include:
• HTA evidence strategy
• submission readiness
• comparator positioning
• value narrative development
• objection handling
• reimbursement planning
JCA Readiness
The introduction of EU Joint Clinical Assessment has changed the evidence landscape.
I help organisations prepare assets, evidence packages and internal governance processes for JCA requirements under the EU HTA Regulation.
This includes strategic alignment of PICOs, comparators, endpoints and clinical evidence narratives to ensure readiness across European markets.
Typical areas include:
• JCA readiness assessments
• PICO framework development
• comparator and endpoint strategy
• evidence synthesis
• cross-functional governance
• global-to-EU alignment
Integrated Evidence Generation
I design integrated evidence generation strategies that align clinical, economic and patient-centred evidence across the development lifecycle.
The aim is to ensure evidence generation is fit for purpose across regulatory, HTA and payer decision-making.
This includes early gap analysis through to late-stage evidence optimisation.
Typical areas include:
• evidence gap analysis
• Systematic and targeted literature reviews
• comparative effectiveness planning
• RWE strategy
• burden of illness evidence
• value dossier alignment
HEOR
I bring senior HEOR expertise grounded in rigorous, data-driven analysis to support evidence-based decision-making and demonstrate value to healthcare systems and payers.
My approach combines strategic insight with hands-on technical delivery across models, utilities and outcomes evidence.
Typical areas include:
• cost-effectiveness modelling
• utility strategy
• scenario analyses
• evidence synthesis
• value demonstration
COA/PRO Strategy
I provide strategic advisory on Clinical Outcome Assessments and Patient-Reported Outcomes, ensuring patient-centred evidence is embedded within development and access plans.
This includes selection, modification and validation of instruments, as well as endpoint strategies that meet both regulatory and HTA expectations.
Typical areas include:
• COA / PRO selection
• conceptual frameworks
• endpoint strategy
• instrument validation
• utility mapping
• psychometric strategy